Peripheral T-cell Lymphoma (PTCL)

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT02314247TerminatedEst. Feb 2016
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
Pralatrexate InjectionPhase 11 trial
Active Trials
NCT02594267CompletedEst. Oct 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Karyopharm TherapeuticsSelinexor
Acrotech BiopharmaPralatrexate Injection

Clinical Trials (2)

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Start: Feb 2015Est. completion: Feb 2016
Phase 2Terminated
NCT02594267Acrotech BiopharmaPralatrexate Injection

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Start: Nov 2015Est. completion: Oct 2020
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space